{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE', 'Signature of Site Principal Investigator', 'dd mmm yyyy', 'Printed Name of Site Principal Investigator', 'Institution Name:', 'By my signature, I agree to personally supervise the conduct of this study at my study', 'site and to ensure its conduct is in compliance with the protocol, informed consent,', 'Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from', 'Amgen representatives, the Declaration of Helsinki, International Council for', 'Harmonisation (ICH) Good Clinical Practices Guidelines, and local regulations', 'governing the conduct of clinical studies.', 'Confidential and Proprietary', '4', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'COORDINATING PRINCIPAL INVESTIGATOR SIGNATURE PAGE', 'Signature of Coordinating Principal Investigator', 'dd mmm yyyy', 'Printed Name of Coordinating Principal Investigator', 'Institution Name:', 'By my signature, I agree the protocol has been written to comply with ICH Good', 'Clinical Practices guidelines and agree to offer guidance throughout the study as', 'needed.', 'Confidential and Proprietary', '5', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'PROTOCOL SUMMARY', 'Study Title', 'A phase 4, multi-center, randomized, double-blind, placebo-controlled study of the impact of', 'apremilast (CC-10004) on quality of life, efficacy, and safety in subjects with manifestations of', 'plaque psoriasis and impaired quality of life.', 'Indication', 'Psoriasis vulgaris is a chronic inflammatory immunologic disorder which manifests primarily in', 'the skin. It is characterized by sharply demarcated areas of affected skin which appear thickened,', 'red, and scaly. The scalp, elbows, knees, lower back, hands, and feet are commonly affected', 'sites. About 80% of affected patients complain of pruritus (Gottlieb, 1998). The psoriatic', 'appearance of the skin is initiated by an antigen presenting cell (APC) - T-cell interaction', 'leading to the release of multiple inflammatory cytokines (Nestle, 2009). In time, this leads to an', 'increased rate of epidermal proliferation with impaired differentiation of keratinocytes, resulting', 'in a thickened epidermis covered by a thickened, parakeratotic stratum corneum. Dermal', 'capillaries become tortuous and dilated, and there is infiltration of both epidermis and dermis', 'with imunologically active cells (Lowes, 2007).', 'According to a European consensus statement on the definition of treatment goals for patients', 'with plaque psoriasis, mild psoriasis is defined as body surface area (BSA) < 10% and Psoriasis', 'Area Severity Index (PASI) < 10 and Dermatology Life Quality Index (DLQI) 10. However,', 'patients with mild psoriasis, as indicated by the somatic scores, BSA and PASI, may present with', 'disease manifestations not adequately controlled by topical therapy alone which, in addition, may', 'lead to a significantly impaired quality of life. These manifestations can include the following:', 'involvement of visible areas, involvement of major parts of the scalp, involvement of genitals,', 'involvement of palms and/or soles, onycholysis or onychodystrophy of at least two fingernails,', 'pruritus leading to scratching, and presence of single recalcitrant plaques.', 'The presence of any of the previously mentioned manifestations alters the classification of mild', 'psoriasis to moderate to severe psoriasis in need of systemic therapy due to significantly', 'impaired quality of life (Mrowietz, 2011).', 'Objectives', 'Primary Objective', 'To assess the impact of apremilast 30 mg twice daily (BID), compared to placebo,', 'on Health-related Quality of Life (QOL) in subjects with manifestations of plaque', 'psoriasis and impaired quality of life at Week 16', 'Secondary Objectives', 'To assess the efficacy and safety of apremilast 30 mg BID, compared to placebo', 'in subjects with manifestations of plaque psoriasis and impaired quality of life at', 'Week 16', 'To assess the long-term effects of apremilast 30 mg BID, with respect to quality', 'of life, efficacy, and safety at Weeks 32 and 52', 'Confidential and Proprietary', '6', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']\n\n###\n\n", "completion": "END"}